User login
Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.
Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.
Investors
3:59 PM EDT • Jun 16, 2021
QTNT
4.25USD
-0.24%
Contact
Peter Buhler, Chief Financial Officer
IR@quotientbd.com
3 Months
6 Months
12 Months
Quotient Ltd
USD
Events & presentations
Quotient Limited to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
Quotient Limited to Participate in Jefferies Virtual Healthcare Conference
Press releases
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update
Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.